Michael E Nesheim
Overview
Explore the profile of Michael E Nesheim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
355
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sidelmann J, Booth N, Hoffmann J, Nesheim M, Rosen S
EJIFCC
. 2018 Dec;
12(3):83-91.
PMID: 30532684
There is a lack of well-established criteria for the specific measurement of fibrinolytic variables. On behalf of the SSC the Subcommittee on Fibrinolysis started a process to develop such criteria....
2.
Owczarek D, Undas A, Foley J, Nesheim M, Jablonski K, Mach T
J Crohns Colitis
. 2012 Jan;
6(1):13-20.
PMID: 22261523
Background: Thrombin activatable fibrinolysis inhibitor (TAFI) has been reported to be involved in the pathogenesis and progression of inflammatory bowel disease (IBD). Activated TAFI (TAFIa) attenuates fibrinolysis by cleaving C-terminal...
3.
Foley J, Petersen K, Rea C, Harpell L, Powell S, Lillicrap D, et al.
Blood
. 2012 Jan;
119(15):3622-8.
PMID: 22234684
Solulin is a soluble form of thrombomodulin that is resistant to proteolysis and oxidation. It has been shown to increase the clot lysis time in factor VIII (fVIII)-deficient plasma by...
4.
Kim P, Kim P, Taylor Jr F, Nesheim M
J Thromb Thrombolysis
. 2012 Jan;
33(4):412-5.
PMID: 22228479
Activated thrombin-activatable fibrinolysis inhibitor (TAFIa or CPU) is a carboxypeptidase that is able to attenuate fibrinolysis. Although its role in fibrinolysis and inflammation has been studied extensively in vitro, its...
5.
6.
Foley J, Cook P, Nesheim M
J Biol Chem
. 2011 Apr;
286(22):19280-6.
PMID: 21467042
Partial digestion of fibrin by plasmin exposes C-terminal lysine residues, which comprise new binding sites for both plasminogen and tissue-type plasminogen activator (tPA). This binding increases the catalytic efficiency of...
7.
Yan D, Stocco R, Sawyer N, Nesheim M, Abramovitz M, Funk C
Mol Pharmacol
. 2010 Nov;
79(2):270-8.
PMID: 21078884
The cysteinyl leukotrienes (cysLTs) LTC₄, LTD₄, and LTE₄ are lipid mediators with physiological and pathophysiological functions. They exert their effects through G protein-coupled receptors (GPCRs), most notably via CysLT₁ and...
8.
Kim P, Nesheim M
Thromb Haemost
. 2010 Apr;
104(1):61-70.
PMID: 20390226
Activated protein C (aPC) proteolytically inactivates factor Va (FVa) and thereby downregulates prothrombinase. Although FVa inactivation by aPC has been studied extensively, the inactivation of prothrombinase during prothrombin activation has...
9.
Kim P, Manuel R, Nesheim M
Thromb Haemost
. 2009 Oct;
102(4):623-33.
PMID: 19806247
Human and bovine factor Va (FVa) function similarly in the activation of prothrombin but differently in the activation of prethrombin-1 (Pre-1). Pre-1 activation with human FVa proceeds at about 22...
10.
Wu C, Kim P, Manuel R, Seto M, Whitlow M, Nagashima M, et al.
J Biol Chem
. 2008 Dec;
284(11):7059-67.
PMID: 19074424
Thrombomodulin (TM) increases the catalytic efficiency of thrombin (IIa)-mediated activation of thrombin-activable fibrinolysis inhibitor (TAFI) 1250-fold. Negatively charged residues of the C-loop of TM-EGF-like domain 3 are required for TAFI...